SCHEMBL29936652

SCHEMBL29936652

O=S1(=O)CCN(Cc2cc(NC3CCOCC3)c3[nH]c(-c4cccc(F)c4)cc3c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 2/20 0.39
CSF1R P07333 1/20 0.38
PDE4B Q07343 1/20 0.35
CHEK1 O14757 1/20 0.35
KCNH2 Q12809 1/20 0.35
INSR P06213 2/20 0.35
IGF1R P08069 2/20 0.35
ALK Q9UM73 2/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
LMNA P02545 1/20 0.34
CCR3 P51677 1/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995328 1.00 VCP (0.39) VCPCSF1RPDE4BCHEK1KCNH2
SCHEMBL3415489 0.92 VCP (0.40) VCPCHEK1KCNH2DRD2DRD4
SCHEMBL29386984 0.91 CSF1R (0.42) VCPCSF1RDRD2DRD4RAB9A
SCHEMBL1897623 0.91 CSF1R (0.42) VCPCSF1RDRD2DRD4RAB9A
SCHEMBL25333094 0.88 MEN1 (0.43) VCPCSF1RPDE4BCHEK1KCNH2
Sulfuric Acid SCHEMBL30014339 0.87 CSF1R (0.39) VCPCSF1RALDH1A1RAB9AADORA1
SCHEMBL27821646 0.85 CHEK1 (0.35) VCPCSF1RCHEK1KCNH2INSR
SCHEMBL3000481 0.83 ACP1 (0.41) CSF1RDRD4CCR3SMN1; SMN2MCHR1
SCHEMBL25332392 0.82 CSF1R (0.42) VCPCSF1RRAB9AADORA1
SCHEMBL3418751 0.81 ALDH1A1 (0.40) CSF1RLMNAALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024191106-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF EPILEPSY 주식회사 미토이뮨테라퓨틱스 2024-09-19 WO claimed
CN-118647383-A Anti-ovarian aging pharmaceutical composition and application thereof 水疗免疫疗法有限公司 2024-09-13 CN claimed
WO-2023182840-A1 ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF 주식회사 미토이뮨테라퓨틱스 2023-09-28 WO claimed
WO-2022220517-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME 주식회사 미토이뮨테라퓨틱스 2022-10-20 WO claimed
US-20250213583-A1 ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF MITOIMMUNE THERAPEUTICS INC. (KR) 2025-07-03 US disclosed
US-20250082646-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF MITOIMMUNE THERAPEUTICS INC. (KR) 2025-03-13 US disclosed
US-20240374646-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME MITOIMMUNE THERAPEUTICS INC. (KR) 2024-11-14 US disclosed
US-20240269145-A1 USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS MITOIMMUNE THERAPEUTICS INC. (KR) 2024-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374646-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME TFAM, FIS1, AIFM1 VCP 1138/4885CSF1R 1534/4885PDE4B 3527/4885
US-20250082646-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP19A1, NR5A1, CYP11A1 VCP 602/4885CSF1R 4503/4885PDE4B 768/4885
US-20250213583-A1 ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF ZC3HAV1, ZC3HAV1L, SARS1 VCP 2469/4885CSF1R 3618/4885PDE4B 1314/4885
US-20240269145-A1 USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS AIFM2, FECH, SLC40A1 VCP 3822/4885CSF1R 1524/4885PDE4B 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.